132 related articles for article (PubMed ID: 9848870)
1. Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy.
Mastronardi L; Puzzilli F; Guiducci A
Neurosurgery; 1998 Dec; 43(6):1496. PubMed ID: 9848870
[No Abstract] [Full Text] [Related]
2. Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy.
Hilton DA; Love S; Barber R; Ellison D; Sandeman DR
Neurosurgery; 1998 Apr; 42(4):724-9. PubMed ID: 9574635
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival.
Hilton DA; Penney M; Evans B; Sanders H; Love S
Am J Surg Pathol; 2002 Apr; 26(4):472-8. PubMed ID: 11914625
[TBL] [Abstract][Full Text] [Related]
4. Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies.
Ellison DW; Steart PV; Bateman AC; Pickering RM; Palmer JD; Weller RO
J Neurol Neurosurg Psychiatry; 1995 Oct; 59(4):413-9. PubMed ID: 7561922
[TBL] [Abstract][Full Text] [Related]
5. [Postoperative radiation therapy of malignant glioma--results of conventional radiation therapy].
Teshima T; Inoue T; Chatani M; Hata K; Taki T; Nii Y; Nakagawa H
Nihon Gan Chiryo Gakkai Shi; 1987 Feb; 22(1):33-9. PubMed ID: 3611889
[No Abstract] [Full Text] [Related]
6. Molecular markers relating to malignant progression in Grade II astrocytoma.
Yue WY; Yu SH; Zhao SG; Chen ZP
J Neurosurg; 2009 Apr; 110(4):709-14. PubMed ID: 19025355
[TBL] [Abstract][Full Text] [Related]
7. [Current status of radiation therapy in the treatment of malignant glioma:].
Tanaka Y; Watari T; Takai Y; Niibe H; Kita M; Shimizu T; Takahashi M; Mitomo M; Jingu K; Maehara F
Gan No Rinsho; 1989 Sep; 35(11):1233-9. PubMed ID: 2681870
[TBL] [Abstract][Full Text] [Related]
8. [Results of conventional radiotherapy in malignant gliomas:].
Shibamoto Y; Yamashita J; Takahashi M; Yamasaki T; Kikuchi H; Abe M
Gan No Rinsho; 1989 Sep; 35(11):1240-6. PubMed ID: 2554004
[TBL] [Abstract][Full Text] [Related]
9. Management of optic pathway tumors of childhood.
Wisoff JH
Neurosurg Clin N Am; 1992 Oct; 3(4):791-802. PubMed ID: 1392576
[No Abstract] [Full Text] [Related]
10. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
[TBL] [Abstract][Full Text] [Related]
11. [Possibilities of quantitative criteria of the effectiveness of treatment of glial brain tumors].
Kachkov IA; Timofeeva TV
Zh Vopr Neirokhir Im N N Burdenko; 1987; (4):37-40. PubMed ID: 3673429
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis and p53 expression in human gliomas.
Sipos L; Szegedi Z; Fedorcsák I; Afra D; Szende B
Pathol Oncol Res; 1998; 4(4):267-70. PubMed ID: 9887356
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas.
Suzuki S; Oka H; Kawano N; Tanaka S; Utsuki S; Fujii K
Brain Tumor Pathol; 2001; 18(2):151-4. PubMed ID: 11908872
[TBL] [Abstract][Full Text] [Related]
14. CDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas.
Suren D; Isiksacan Ozen O
J BUON; 2013; 18(4):1006-11. PubMed ID: 24344030
[TBL] [Abstract][Full Text] [Related]
15. p53 immunohistochemical positivity as a prognostic marker in intracranial tumours.
Soini Y; Niemelä A; Kamel D; Herva R; Bloigu R; Pääkkö P; Vähäkangas K
APMIS; 1994 Oct; 102(10):786-92. PubMed ID: 7826609
[TBL] [Abstract][Full Text] [Related]
16. Locoregional approaches to therapy with gliomas as the paradigm.
Liang BC; Weil M
Curr Opin Oncol; 1998 May; 10(3):201-6. PubMed ID: 9619355
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological correlation of cell proliferation, apoptosis and p53 in cerebellar pilocytic astrocytomas.
Haapasalo H; Sallinen S; Sallinen P; Helén P; Jääskeläinen J; Salmi TT; Paetau A; Paljärvi L; Visakorpi T; Kalimo H
Neuropathol Appl Neurobiol; 1999 Apr; 25(2):134-42. PubMed ID: 10216001
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature.
Reavey-Cantwell JF; Haroun RI; Zahurak M; Clatterbuck RE; Parker RJ; Mehta R; Fruehauf JP; Brem H
J Neurooncol; 2001 Dec; 55(3):195-204. PubMed ID: 11859975
[TBL] [Abstract][Full Text] [Related]
19. Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corroborating clinical response in vitro: case report.
Zhang W; Hinton DR; Surnock AA; Couldwell WT
Neurosurgery; 1996 Mar; 38(3):587-90; discussion 590-1. PubMed ID: 8837815
[TBL] [Abstract][Full Text] [Related]
20. Cytoplasmic localization of wild-type p53 in glioblastomas correlates with expression of vimentin and glial fibrillary acidic protein.
Sembritzki O; Hagel C; Lamszus K; Deppert W; Bohn W
Neuro Oncol; 2002 Jul; 4(3):171-8. PubMed ID: 12084347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
